Orbis Investment Advisory Limited is a privately owned investment manager based in London, United Kingdom. Established in 1989, the firm offers a range of services to both institutions and individuals, managing equity, fixed income, and balanced mutual funds. Orbis focuses on global public equity and fixed income markets, employing a fundamental, long-term, and contrarian investment philosophy. The firm primarily invests in value stocks and utilizes both fundamental and quantitative analysis, emphasizing a bottom-up approach in its investment strategies. Orbis benchmarks its portfolio performance against various indices, including MSCI and JP Morgan Global Government Bond Index. As a subsidiary of Orbis Group, the firm manages around $30 billion in assets, drawing on the expertise of approximately 400 employees from diverse backgrounds across eight countries.
Peplin is a development-stage specialty pharmaceutical company focused on advancing and commercializing medical dermatology products. The Company is developing PEP005 (ingenol mebutate) (PEP005), which is derived from Euphorbia peplus (E. peplus), a plant referred to as petty spurge or radium weed. Peplin’s lead product candidate, which is in Phase III clinical trials, is a patient-applied topical gel containing PEP005, a compound used for the treatment of actinic keratosis (AK). Peplin’s other product candidate is a physician-applied topical gel for the treatment of superficial basal cell carcinoma (superficial BCC), PEP005 Gel for BCC. The active compound in each product is a small molecule extracted and purified from the sap of E. peplus. On October 16, 2008, the Company acquired Neosil, Inc., a dermatology-focused company. Later on, Peplin, Inc. was acquired by LEO Pharma A/S.